Autologous Cell Therapy Market Report 2026
Global Outlook – By Therapy (Autologous Stem Cell Therapy, Autologous Cellular Immunotherapies), By Source (Bone Marrow, Epidermis, Mesenchymal Stem Cells, Hematopoietic Stem Cells, Chondrocytes, Other Sources), By Application (Cancer, Neurodegenerative Disorders, Cardiovascular Disorders, Autoimmune Disorders, Orthopedics, Wound Healing, Other Applications), By End User (Hospitals And Clinics, Ambulatory Centers, Academics And Research, Other End-Users) - Market Size, Trends, Strategies, and Forecast to 2030
Autologous Cell Therapy Market Overview
• Autologous Cell Therapy market size has reached to $12.14 billion in 2025 • Expected to grow to $27.31 billion in 2030 at a compound annual growth rate (CAGR) of 17.6% • Growth Driver: High Prevalence Of Chronic Diseases Drives Growth In Autologous Cell Therapy Market • Market Trend: Adoption of automated, closed-loop manufacturing systems in autologous cell therapy to enhance scalability and process efficiency • North America was the largest region in 2025 and Asia-pacific is the fastest growing region.What Is Covered Under Autologous Cell Therapy Market?
Autologous cell therapy refers to a type of cell therapy where a patient's cells are collected, processed, and then reintroduced into their own body for therapeutic purposes. It is often used in regenerative medicine to repair, replace, or restore damaged tissues or organs. The main types of autologous cell therapy are autologous stem cell therapy and autologous cellular immunotherapies. Autologous stem cell therapy is a specific form of autologous cell therapy that utilizes stem cells derived from the patient's body for therapeutic purposes. The different sources include bone marrow, epidermis, mesenchymal stem cells, Hematopoietic stem cells, chondrocytes, and others, that are applied in cancer, neurodegenerative disorders, cardiovascular disorders, autoimmune disorders, orthopedics, wound healing, and others. It is used by hospitals and clinics, ambulatory centers, academics and research, and others.
What Is The Autologous Cell Therapy Market Size and Share 2026?
The autologous cell therapy market size has grown rapidly in recent years. It will grow from $12.14 billion in 2025 to $14.28 billion in 2026 at a compound annual growth rate (CAGR) of 17.6%. The growth in the historic period can be attributed to advancements in stem cell research, early clinical success of autologous therapies, increasing prevalence of chronic diseases, expansion of oncology treatment options, rising investments in regenerative medicine.What Is The Autologous Cell Therapy Market Growth Forecast?
The autologous cell therapy market size is expected to see rapid growth in the next few years. It will grow to $27.31 billion in 2030 at a compound annual growth rate (CAGR) of 17.6%. The growth in the forecast period can be attributed to increasing approvals of cell-based therapies, growing demand for personalized medicine, expansion of manufacturing automation in cell therapy, rising clinical trial activity, increasing healthcare spending on advanced therapies. Major trends in the forecast period include increasing adoption of car t-cell therapies, rising use of personalized regenerative treatments, growing integration of automated cell processing systems, expansion of autologous stem cell applications, enhanced focus on patient-specific therapeutic outcomes.
Global Autologous Cell Therapy Market Segmentation
1) By Therapy: Autologous Stem Cell Therapy, Autologous Cellular Immunotherapies 2) By Source: Bone Marrow, Epidermis, Mesenchymal Stem Cells, Hematopoietic Stem Cells, Chondrocytes, Other Sources 3) By Application: Cancer, Neurodegenerative Disorders, Cardiovascular Disorders, Autoimmune Disorders, Orthopedics, Wound Healing, Other Applications 4) By End User: Hospitals And Clinics, Ambulatory Centers, Academics And Research, Other End-Users Subsegments: 1) By Autologous Stem Cell Therapy: Hematopoietic Stem Cell Transplantation, Mesenchymal Stem Cell Therapy, Adipose-Derived Stem Cell Therapy 2) By Autologous Cellular Immunotherapies: Chimeric Antigen Receptor (CAR) T-Cell Therapy, Tumor-Infiltrating Lymphocyte (TIL) Therapy, Dendritic Cell TherapyWhat Is The Driver Of The Autologous Cell Therapy Market?
The high prevalence of chronic diseases is expected to drive the growth of autologous cell therapy. Chronic disease is a condition or illness that lasts more than a year and requires ongoing medical treatment. Autologous cell therapy offers a promising approach for treating and managing these conditions that uses an individual's cells, which are cultivated and enlarged outside the body before being reintroduced into the donor. For instance, in January 2023, according to the National Library of Medicine, a US-based agency, the number of people in the US aged 50 and older who have at least 1 chronic condition will increase to 142.66 million by 2050. Thus, the high prevalence of chronic diseases is driving the growth of the autologous cell therapy industry.Key Players In The Global Autologous Cell Therapy Market
Major companies operating in the autologous cell therapy market are Novartis AG, Bristol-Myers Squibb Company, Gilead Sciences Inc., Johnson & Johnson, F. Hoffmann-La Roche Ltd., Vericel Corporation, Dendreon Pharmaceuticals LLC, Brainstorm Cell Therapeutics Inc., Caladrius Biosciences Inc., Castle Creek Biosciences Inc., Pharmicell Co. Ltd., Medipost Co. Ltd., Tego Science AB, Holostem Terapie Avanzate S.r.l., Opexa Therapeutics Inc., CORESTEM Inc., Takeda Pharmaceutical Company Limited, CSL Limited, AstraZeneca plc, Iovance Biotherapeutics Inc., Adaptimmune Therapeutics plc, Autolus Therapeutics plc
This chart is for illustrative purposes; the full report includes a detailed competitor analysis and comprehensive overview of the top 10 companies in the market.
This chart maps companies by product innovation and brand strength, with bubble size indicating relative revenue, helping identify market leaders, challengers, and niche players. This is an illustrative chart; the full report provides a complete and accurate competitive analysis.
Explore how leading companies compare across key metrics in our report Get Report
Global Autologous Cell Therapy Market Trends and Insights
Major companies are operating in the autologous cell therapy market, focusing on developing technological advancements such as robotic, end-to-end manufacturing platforms for patient-specific therapies to improve process consistency, reduce contamination risk, and accelerate time-to-patient. An end-to-end manufacturing platform integrates multiple cell-processing steps, including isolation, activation, transduction, expansion, formulation, and harvest within a single closed system, reducing manual intervention compared to traditional open flask- or bag-based methods. For instance, in April 2025, Cellares, a US-based integrated development and manufacturing organization, launched the Cell Shuttle system designed for autologous cell therapies. The product automates the entire workflow in a functionally closed cassette, enhances reproducibility, minimizes contamination risk, and enables scalable, patient-specific manufacturing, supporting faster development and delivery of personalized therapies.What Are Latest Mergers And Acquisitions In The Autologous Cell Therapy Market?
In October 2023, Clade Therapeutics, a US-based cell therapy company, acquired Gadeta B.V. for an undisclosed amount. The acquisition adds cell therapies, such as innovative gamma/delta (g/d) T-cell receptor (TCR)-based immunotherapies for cancer patients, to Clade’s portfolio of offerings. Gadeta B.V. is a Netherlands-based cell therapy company.
Regional Outlook
North America was the largest region in the autologous cell therapy market in 2025.Asia-pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.Need data for a specific geography? Request Regional Data
What Defines the Autologous Cell Therapy Market?
The autologous cell therapy market includes revenues earned by providing services in relation to cell collection, cell processing, cell expansion, or its modification. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.How is Market Value Defined and Measured?
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This chart presents market attractiveness based on a quantitative evaluation of growth, competition, strategic alignment, and risk, offering a clear view of opportunity areas for decision-making. This chart is for illustrative purposes; the full report contains the complete analysis.
This chart highlights the Total Addressable Market (TAM) by estimating the maximum revenue opportunity using an assumption-driven approach, supporting strategic planning and opportunity sizing across markets. The chart is illustrative; the full report provides a more comprehensive analysis.
Access full TAM calculations and growth projections in our report Get Report
What Key Data and Analysis Are Included in the Autologous Cell Therapy Market Report 2026?
The autologous cell therapy market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the autologous cell therapy industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.Autologous Cell Therapy Market Report Forecast Analysis
| Report Attribute | Details |
|---|---|
| Market Size Value In 2026 | $14.28 billion |
| Revenue Forecast In 2030 | $27.31 billion |
| Growth Rate | CAGR of 17.6% from 2026 to 2030 |
| Base Year For Estimation | 2025 |
| Actual Estimates/Historical Data | 2020-2025 |
| Forecast Period | 2026 - 2030 |
| Market Representation | Revenue in USD Billion and CAGR from 2026 to 2030 |
| Segments Covered | Therapy, Source, Application, End User |
| Regional Scope | Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa |
| Country Scope | The countries covered in the report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain |
| Key Companies Profiled | Novartis AG, Bristol-Myers Squibb Company, Gilead Sciences Inc., Johnson & Johnson, F. Hoffmann-La Roche Ltd., Vericel Corporation, Dendreon Pharmaceuticals LLC, Brainstorm Cell Therapeutics Inc., Caladrius Biosciences Inc., Castle Creek Biosciences Inc., Pharmicell Co. Ltd., Medipost Co. Ltd., Tego Science AB, Holostem Terapie Avanzate S.r.l., Opexa Therapeutics Inc., CORESTEM Inc., Takeda Pharmaceutical Company Limited, CSL Limited, AstraZeneca plc, Iovance Biotherapeutics Inc., Adaptimmune Therapeutics plc, Autolus Therapeutics plc |
| Customization Scope | Request for Customization |
| Pricing And Purchase Options | Explore Purchase Options |